The utility of MRI in suspected MS

Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology

Elliot Frohman, D. S. Goodin, P. A. Calabresi, J. R. Corboy, P. K. Coyle, M. Filippi, J. A. Frank, S. L. Galetta, R. I. Grossman, K. Hawker, N. J. Kachuck, M. C. Levin, J. T. Phillips, M. K. Racke, V. M. Rivera, W. H. Stuart

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently, confirmation of the diagnosis of MS has generally required the demonstration of clinical activity that is disseminated in both time and space. Nevertheless, with the advent of MRI techniques, occult disease activity can be demonstrated in 50 to 80% of patients at the time of the first clinical presentation. Prospective studies have shown that the presence of such lesions predicts future conversion to clinically definite (CD) MS. Indeed, in a young to middle-aged adult with a clinically isolated syndrome (CIS), once alternative diagnoses are excluded at baseline, the finding of three or more white matter lesions on a T2-weighted MRI scan (especially if one of these lesions is located in the periventricular region) is a very sensitive predictor (>80%) of the subsequent development of CDMS within the next 7 to 10 years. Moreover, the presence of two or more gadolinium (Gd)-enhancing lesions at baseline and the appearance of either new T2 lesions or new Gd enhancement on follow-up scans are also highly predictive of the subsequent development of CDMS in the near term. By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely.

Original languageEnglish (US)
Pages (from-to)602-611
Number of pages10
JournalNeurology
Volume61
Issue number5
StatePublished - Sep 9 2003

Fingerprint

Biomedical Technology Assessment
Gadolinium
Therapeutics
Magnetic Resonance Imaging
Prospective Studies
Technology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Frohman, E., Goodin, D. S., Calabresi, P. A., Corboy, J. R., Coyle, P. K., Filippi, M., ... Stuart, W. H. (2003). The utility of MRI in suspected MS: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology, 61(5), 602-611.

The utility of MRI in suspected MS : Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. / Frohman, Elliot; Goodin, D. S.; Calabresi, P. A.; Corboy, J. R.; Coyle, P. K.; Filippi, M.; Frank, J. A.; Galetta, S. L.; Grossman, R. I.; Hawker, K.; Kachuck, N. J.; Levin, M. C.; Phillips, J. T.; Racke, M. K.; Rivera, V. M.; Stuart, W. H.

In: Neurology, Vol. 61, No. 5, 09.09.2003, p. 602-611.

Research output: Contribution to journalArticle

Frohman, E, Goodin, DS, Calabresi, PA, Corboy, JR, Coyle, PK, Filippi, M, Frank, JA, Galetta, SL, Grossman, RI, Hawker, K, Kachuck, NJ, Levin, MC, Phillips, JT, Racke, MK, Rivera, VM & Stuart, WH 2003, 'The utility of MRI in suspected MS: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology', Neurology, vol. 61, no. 5, pp. 602-611.
Frohman, Elliot ; Goodin, D. S. ; Calabresi, P. A. ; Corboy, J. R. ; Coyle, P. K. ; Filippi, M. ; Frank, J. A. ; Galetta, S. L. ; Grossman, R. I. ; Hawker, K. ; Kachuck, N. J. ; Levin, M. C. ; Phillips, J. T. ; Racke, M. K. ; Rivera, V. M. ; Stuart, W. H. / The utility of MRI in suspected MS : Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. In: Neurology. 2003 ; Vol. 61, No. 5. pp. 602-611.
@article{6d40a460ce3b47fc97fa4a95bbbafea9,
title = "The utility of MRI in suspected MS: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology",
abstract = "Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently, confirmation of the diagnosis of MS has generally required the demonstration of clinical activity that is disseminated in both time and space. Nevertheless, with the advent of MRI techniques, occult disease activity can be demonstrated in 50 to 80{\%} of patients at the time of the first clinical presentation. Prospective studies have shown that the presence of such lesions predicts future conversion to clinically definite (CD) MS. Indeed, in a young to middle-aged adult with a clinically isolated syndrome (CIS), once alternative diagnoses are excluded at baseline, the finding of three or more white matter lesions on a T2-weighted MRI scan (especially if one of these lesions is located in the periventricular region) is a very sensitive predictor (>80{\%}) of the subsequent development of CDMS within the next 7 to 10 years. Moreover, the presence of two or more gadolinium (Gd)-enhancing lesions at baseline and the appearance of either new T2 lesions or new Gd enhancement on follow-up scans are also highly predictive of the subsequent development of CDMS in the near term. By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely.",
author = "Elliot Frohman and Goodin, {D. S.} and Calabresi, {P. A.} and Corboy, {J. R.} and Coyle, {P. K.} and M. Filippi and Frank, {J. A.} and Galetta, {S. L.} and Grossman, {R. I.} and K. Hawker and Kachuck, {N. J.} and Levin, {M. C.} and Phillips, {J. T.} and Racke, {M. K.} and Rivera, {V. M.} and Stuart, {W. H.}",
year = "2003",
month = "9",
day = "9",
language = "English (US)",
volume = "61",
pages = "602--611",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The utility of MRI in suspected MS

T2 - Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology

AU - Frohman, Elliot

AU - Goodin, D. S.

AU - Calabresi, P. A.

AU - Corboy, J. R.

AU - Coyle, P. K.

AU - Filippi, M.

AU - Frank, J. A.

AU - Galetta, S. L.

AU - Grossman, R. I.

AU - Hawker, K.

AU - Kachuck, N. J.

AU - Levin, M. C.

AU - Phillips, J. T.

AU - Racke, M. K.

AU - Rivera, V. M.

AU - Stuart, W. H.

PY - 2003/9/9

Y1 - 2003/9/9

N2 - Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently, confirmation of the diagnosis of MS has generally required the demonstration of clinical activity that is disseminated in both time and space. Nevertheless, with the advent of MRI techniques, occult disease activity can be demonstrated in 50 to 80% of patients at the time of the first clinical presentation. Prospective studies have shown that the presence of such lesions predicts future conversion to clinically definite (CD) MS. Indeed, in a young to middle-aged adult with a clinically isolated syndrome (CIS), once alternative diagnoses are excluded at baseline, the finding of three or more white matter lesions on a T2-weighted MRI scan (especially if one of these lesions is located in the periventricular region) is a very sensitive predictor (>80%) of the subsequent development of CDMS within the next 7 to 10 years. Moreover, the presence of two or more gadolinium (Gd)-enhancing lesions at baseline and the appearance of either new T2 lesions or new Gd enhancement on follow-up scans are also highly predictive of the subsequent development of CDMS in the near term. By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely.

AB - Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently, confirmation of the diagnosis of MS has generally required the demonstration of clinical activity that is disseminated in both time and space. Nevertheless, with the advent of MRI techniques, occult disease activity can be demonstrated in 50 to 80% of patients at the time of the first clinical presentation. Prospective studies have shown that the presence of such lesions predicts future conversion to clinically definite (CD) MS. Indeed, in a young to middle-aged adult with a clinically isolated syndrome (CIS), once alternative diagnoses are excluded at baseline, the finding of three or more white matter lesions on a T2-weighted MRI scan (especially if one of these lesions is located in the periventricular region) is a very sensitive predictor (>80%) of the subsequent development of CDMS within the next 7 to 10 years. Moreover, the presence of two or more gadolinium (Gd)-enhancing lesions at baseline and the appearance of either new T2 lesions or new Gd enhancement on follow-up scans are also highly predictive of the subsequent development of CDMS in the near term. By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely.

UR - http://www.scopus.com/inward/record.url?scp=10744223596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223596&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 602

EP - 611

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -